MacroGenics (MGNX) FDA catalyst dates

FreeBioList tracks 3 upcoming catalysts for MacroGenics (MGNX, listed on Nasdaq). They cover 3 programmes: MGC026 (Advanced solid tumours (B7-H3 ADC)), MGC028 (Advanced solid tumours (ADAM9 ADC)) and Lorigerlimab (Clear cell gynaecologic cancer (PD-1 x CTLA-4)).

First on the list: the Phase 1 readout for MGC026 (Advanced solid tumours (B7-H3 ADC)), guided by the company to Oct 2026. The furthest-out event tracked is H1 2027. By stage, the upcoming rows are 2 Phase 1 readouts and 1 Phase 2 readout.

All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
MacroGenics MGNX · Nasdaq	MGC026	Advanced solid tumours (B7-H3 ADC)	Oct 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states interim Phase 1 results were "accepted for poster presentation at the European Society for Medical Oncology (ESMO) 2026 Congress in October." Source: 8-K exhibit 99.1, filed 13 Aug 2026 · verified 12 Sep 2026
MacroGenics MGNX · Nasdaq	MGC028	Advanced solid tumours (ADAM9 ADC)	Late 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states the company "anticipates providing an update with preliminary clinical results in late 2026." Source: 8-K exhibit 99.1, filed 13 Aug 2026 · verified 12 Sep 2026
MacroGenics MGNX · Nasdaq	Lorigerlimab	Clear cell gynaecologic cancer (PD-1 x CTLA-4)	H1 2027 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states the company "anticipates reporting updated study results in the first half of 2027." Source: 8-K exhibit 99.1, filed 13 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Arcus Biosciences (RCUS)First-line clear cell renal cell carcinoma; Second-line clear cell renal cell carcinoma; First-line metastatic pancreatic ductal adenocarcinoma
Xencor (XNCR)Rheumatoid arthritis (CD20 x CD3); B-cell autoimmune disease (CD19 x CD3); Advanced clear cell renal cell carcinoma (ENPP3 x CD3); Ulcerative colitis (anti-TL1A
Aktis Oncology (AKTS)Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical); Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical)
Aprea Therapeutics (APRE)Advanced solid tumours (WEE1 inhibitor)
Arvinas (ARVN)KRAS G12D-mutant solid tumours (degrader); Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader); Parkinson’s disease (LRRK2 degrader) — biomarker data; Kenn
Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)

Also due in Q4 2026

MBX Biosciences (MBX)Phase 1 readout for MBX 4291, Q4 2026
Enanta Pharmaceuticals (ENTA)Phase 1 readout for EDP-978, Q4 2026
Allogene Therapeutics (ALLO)Phase 1 readout for ALLO-329, Q4 2026
Kyverna Therapeutics (KYTX)Phase 1 readout for Miv-cel (mivotacel), Q4 2026
Neumora Therapeutics (NMRA)Phase 1 readout for NMRA-511, Q4 2026
Attovia Therapeutics (ATTO)Phase 1B readout for ATTO-1310, Q4 2026